Efektivitas Vaksin Varicella dalam Mencegah Komplikasi Varicella: Literature Review

Authors

  • Mutmainnah Mutmainnah Universitas Muslim Indonesia
  • Nurelly Waspodo Universitas Muslim Indonesia
  • Lisa Yuniati Universitas Muslim Indonesia

DOI:

https://doi.org/10.55606/jurrike.v5i2.10317

Keywords:

Breakthrough Varicella, Complications, Immunization, Vaccine Effectiveness, Varicella Vaccine

Abstract

Varicella is an infectious disease caused by the varicella-zoster virus (VZV) and has a high transmission rate, particularly among children who lack immunity. Although it is generally mild, varicella can cause complications such as secondary bacterial infections, pneumonia, neurological disorders, hematological abnormalities, and other organ complications. This literature review aimed to analyze and summarize scientific evidence regarding the effectiveness of varicella vaccination in preventing infection, reducing disease severity, and lowering the risk of varicella complications. This study employed a literature review method by examining 20 previous studies published between 2021 and 2025. The reviewed literature included randomized controlled trials, prospective cohort studies, retrospective observational studies, case-control studies, cross-sectional studies, time-series analyses, systematic reviews, and meta-analyses. The results showed that varicella vaccination is effective in preventing infection and reducing disease severity. The two-dose regimen consistently provided higher protection than a single dose, with effectiveness exceeding 90% in several studies. Vaccination was also associated with reduced cases of breakthrough varicella, disease severity, hospitalization, and benefits through community immunity. Vaccine effectiveness was influenced by the number of doses, age and timing of vaccination, interval since vaccination, and population characteristics. In addition, various studies demonstrated high immunogenicity and a favorable safety profile. In conclusion, optimizing the two-dose vaccination regimen and increasing immunization coverage are important strategies for preventing complications and reducing the burden of varicella.

Downloads

Download data is not yet available.

References

Bibi, Z., Nawaz, A. D., Al Kurbi, M., Fakhroo, S., Ferih, K., Al-Jaber, N., Alex, M., Elawad, K. H., Chivese, T., & Zughaier, S. M. (2023). Real-world effectiveness of the varicella vaccine among children and adolescents in Qatar: A case-control study. Vaccines, 11(10), 1567. https://doi.org/10.3390/vaccines11101567

Bolormaa, E., Lee, Y. H., Choe, Y. J., & Choe, S. A. (2025). Varicella vaccine effectiveness and duration of protection: A systematic review and meta-analysis. Journal of Korean Medical Science, 40(44), e286. https://doi.org/10.3346/jkms.2025.40.e286

Centers for Disease Control and Prevention. (2021). Varicella (chickenpox) vaccination: Information for health care providers. CDC

Chen, D., Li, Y., & Wu, Q. (2022). Effectiveness of varicella vaccine as post-exposure prophylaxis: A meta-analysis. Human Vaccines & Immunotherapeutics, 18(1), 5316–5324. https://doi.org/10.1080/21645515.2021.2009729

Huang, L., Chen, Z., Song, Y., Tan, J., Jia, N., You, W., Yuan, H., Feng, G.-W., Li, C., Luan, C., Quan, Y., & Wang, Y. (2024). Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study. Vaccine, 42(2), 396–401. https://doi.org/10.1016/j.vaccine.2023.10.031

Jiang, F., Zhang, R., Guan, Q., Mu, Q., He, P., Ye, X., Wang, W., Quan, J., Li, J., Liang, L., Zeng, F., Tang, N., Xu, F., Wu, P., Pan, Y., Yu, X., Yu, X., Zheng, L., Zhao, Y., Cai, M., Li, C., Zhong, Y., Cao, X., Yu, Y., Zhang, X., Zhang, T., Wang, P., & Lei, S. (2021). Immunogenicity and safety of a live attenuated varicella vaccine in children 1–12 years of age: A randomized, blinded, controlled, non-inferiority phase 3 clinical trial. Contemporary Clinical Trials, 107, 106489. https://doi.org/10.1016/j.cct.2021.106489

Kawamura, Y., Hattori, F., Higashimoto, Y., Kozawa, K., & Yoshikawa, T. (2021). Evaluation of varicella vaccine effectiveness during outbreaks in schools or nurseries by cross-sectional study. Vaccine, 39(21), 2901–2905. https://doi.org/10.1016/j.vaccine.2021.04.009

Leung, J., Marin, M., & Lopez, A. S. (2022). Decline in severe varicella disease during the United States varicella vaccination program: Hospitalizations and deaths, 1990–2019. The Journal of Infectious Diseases, 226(Supplement_4), S407–S415. https://doi.org/10.1093/infdis/jiac242

Li, Y., Xu, F., Liu, M., Teng, S., Liang, F., & Wang, F. (2024). Effectiveness of two-dose vs. one-dose varicella vaccine in children in Shanghai, China: A prospective cohort study. Frontiers in Public Health, 12, 1320407. https://doi.org/10.3389/fpubh.2024.1320407

Liu, F., Li, Z., Wang, H., Cao, Y., Zhang, N., Wang, F., Wei, R., Zhang, J., & Zhao, Y. (2024). Effectiveness of the varicella vaccine in the real world, a matched case-control study. Vaccine, 42(19), 3968–3973. https://doi.org/10.1016/j.vaccine.2024.05.006

Marin, M., Marti, M., Kambhampati, A., Jeram, S. M., & Seward, J. F. (2016). Global varicella vaccine effectiveness: A meta-analysis. Pediatrics, 137(3), e20153741. https://doi.org/10.1542/peds.2015-3741

Marin, M., Nguyen, H. Q., Keen, C., Jumaan, A. O., Mellen, P. M., Hayes, E. B., & Seward, J. F. (2017). Severe complications of varicella in persons vaccinated with varicella vaccine (breakthrough varicella): A systematic literature review. Journal of the Pediatric Infectious Diseases Society, 6(3), 263–271.

Namazova-Baranova, L., Habib, M. A., Povey, M., Efendieva, K., Fedorova, O., Fedoseenko, M., Ivleva, T., Kovshirina, Y., Levina, J., Lyamin, A., Ogorodova, L., Reshetko, O., Romanenko, V., Ryzhenkova, I., Sidorenko, I., Yakovlev, Y., Zhestkov, A., Tatochenko, V., Scherbakov, M., Shpeer, E. L., & Casabona, G. (2022). A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: Ten-year follow-up in Russian children. Human Vaccines & Immunotherapeutics, 18(1), 1959148. https://doi.org/10.1080/21645515.2021.1959148

Pan, H.-X., Qiu, L.-X., Liang, Q., Chen, Z., Zhang, M.-L., Liu, S., Zhong, G.-H., Zhu, K.-X., Liao, M.-J., Hu, J.-L., Li, J.-X., Xu, J.-B., Fan, Y., Huang, Y., Su, Y.-Y., Huang, S.-J., Wang, W., Han, J.-L., Jia, J.-Z., Zhu, H., Cheng, T., Ye, X.-Z., Li, C.-G., Wu, T., Zhu, F.-C., Zhang, J., & Xia, N.-S. (2024). Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: A randomised, double-blind, controlled, phase 2a trial. The Lancet Infectious Diseases, 24(8), 922–934. https://doi.org/10.1016/S1473-3099(24)00159-2

Pawaskar, M., Siddiqui, M. K., Takyar, J., Sharma, A., & Fergie, J. (2022). Relative efficacy of varicella vaccines: Network meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 38(10), 1777–1786. https://doi.org/10.1080/03007995.2022.2091334

Santos, A. P., et al. (2022). Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil. Vaccine, 40(2), 390–395. https://doi.org/10.1016/j.vaccine.2021.08.008

Shu, M., Zhang, D., Ma, R., Yang, T., & Pan, X. (2022). Long-term vaccine efficacy of a 2-dose varicella vaccine in China from 2011 to 2021: A retrospective observational study. Frontiers in Public Health, 10, 1039537. https://doi.org/10.3389/fpubh.2022.1039537

Sun, X., Zhang, L., Song, X., et al. (2026). Immunogenicity and safety of varicella vaccine co-administered with seasonal influenza vaccine in healthy children aged 7–12 years in China. International Journal of Infectious Diseases, 162, 108212. https://doi.org/10.1016/j.ijid.2025.108212

Tavares, R. de O., et al. (2022). Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil. Vaccine, 40(1), 99–105. https://doi.org/10.1016/j.vaccine.2021.08.008

Wang, L., Yang, X., Wang, X., Shi, P., & Zhang, X. (2023). Assessing vaccine effectiveness for varicella in Wuxi, China: A time-series analysis. Annals of Medicine, 55(2), 2246369. https://doi.org/10.1080/07853890.2023.2246369

Wang, S., Zhang, Y., Li, G., Shi, J., Chang, X., Zhang, H., Zhu, F., Li, J., Chu, K., & Sun, J. (2025). Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China. Human Vaccines & Immunotherapeutics, 21(1), 2452681. https://doi.org/10.1080/21645515.2025.2452681

World Health Organization. (2025). WHO position paper on varicella vaccines—November 2025. Weekly Epidemiological Record, 100(47), 567–590. WHO Position Paper on Varicella Vaccines

Yuan, Y., Wang, T., Xia, Y., Shi, Z., & He, P. (2025). Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: A systematic review and meta-analysis. BMC Infectious Diseases, 25(1), 897. https://doi.org/10.1186/s12879-025-11275-w

Zhang, Z., Suo, L., Pan, J., Zhao, D., & Lu, L. (2021). Two-dose varicella vaccine effectiveness in China: A meta-analysis and evidence quality assessment. BMC Infectious Diseases, 21(1), 543. https://doi.org/10.1186/s12879-021-06217-1

Downloads

Published

2026-08-31

How to Cite

Mutmainnah Mutmainnah, Nurelly Waspodo, & Lisa Yuniati. (2026). Efektivitas Vaksin Varicella dalam Mencegah Komplikasi Varicella: Literature Review. JURNAL RISET RUMPUN ILMU KEDOKTERAN, 5(2), 642–658. https://doi.org/10.55606/jurrike.v5i2.10317

Similar Articles

<< < 1 2 3 4 5 6 

You may also start an advanced similarity search for this article.